Diabetes Mellitus Clinical Trial
— OPTIMUMOfficial title:
Optimizing Care of Patients Via Telehealth In Monitoring and Augmenting Their Control of Diabetes Mellitus
OPTIMUM study aims to use the telehealth-enabled chronic disease management programme for individuals with chronic diseases to provide timely intervention to prevent disease deterioration, increase compliance to treatment regimen (e.g. medication), and most importantly, engage participants to better manage their own care.
| Status | Recruiting |
| Enrollment | 330 |
| Est. completion date | July 1, 2022 |
| Est. primary completion date | July 1, 2022 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 26 Years to 65 Years |
| Eligibility |
Inclusion Criteria: 1 . Singapore Citizen or Permanent Resident 2. Age 26 - 65 years (latest age of entry for insurance coverage is 65 at next birthday) 3. Type 2 Diabetes Mellitus (HbA1c = 10% and = 7.5% per latest reading) with and without the following complications: 1. Mild non-proliferative diabetic retinopathy without any macular or retinal involvement; 2. Chronic Kidney Diseases up to stage 3 4. Patients registered with participating polyclinic 5. Non-smoker, or ex-smoker who has completely quit smoking for at least 12 months 6. Existing user of smartphone and is willing to download the relevant mobile application (iPhone or Android phones are acceptable) 7. Expressed willingness to use the telehealth system and devices according to study protocol during the study period Exclusion Criteria: 1. Poorly controlled glycemic control with HbA1c > 10% (latest reading) 2. Cognitively impaired based on diagnosis of dementia or mild cognitive impairment (MCI) in the electronic health records (EHR) 3. Existing conditions listed below, as documented in the EHR: 1. Any proliferative diabetic retinopathy (moderate to severe) and any macular or other retinal complications; 2. Chronic kidney disease Stage 4 or 5; 3. Coronary arterial diseases. 4. Cerebrovascular diseases such as transient ischemic attach (TIA) or stroke; 5. Peripheral vascular disease (result from diabetic foot screening); 6. Known cognitive impairment, including MCI 4. Not able to use smartphone despite coaching 5. Any end-stage disease with life prognosis of < 2 year 6. Patients who are not willing or are not able to commit to the entire Optimum program 7. Pregnant women 8. Currently enrolled in another study / programme involving a novel therapeutic drug or device |
| Country | Name | City | State |
|---|---|---|---|
| Singapore | Sengkang Polyclinic | Singapore |
| Lead Sponsor | Collaborator |
|---|---|
| SingHealth Polyclinics | MOH Office for Healthcare Transformation (MOHT), Singapore, Phillips Healthcare, Singapore, Reinsurance Group of America (RGA), Singapore |
Singapore,
Berkel C van, Smith M, Horsfield D, McManus H. Evidence for Supported Self-Care at Scale. International Journal of Integrated Care. 2016 Nov 9;16(5):S44.
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Diabetic control | HbA1c (in percentage) | 6 months | |
| Secondary | Diabetic control | HbA1c (in percentage) | 12 months, 24 months | |
| Secondary | Blood pressure control | Systolic and diastolic blood pressure (in mmHg) | 6 months, 12 months, 24 months | |
| Secondary | Optimal weight control | Weight (in kilogram) | 6 months, 12 months, 24 months | |
| Secondary | Utility Score | EQ-5D-5L questionnaire, reported as index value by applying the formula. the higher the score the better. * EQ-5D-5L is not an abbreviation |
6 months, 12 months, 24 months | |
| Secondary | Diabetic medication adherence 9 Diabetic medication adherence (Oral Hypoglycemia agent) | Medication Adherence Rating Scale 5 (MARS 5) - max score of 25, min score of 5 (the higher the score the better the adherence) | 6 months, 12 months, 24 months | |
| Secondary | Diabetic medication adherence (Insulin) | Medication possession ratio (MPR) - max score of 1, min score of 0, higher number indicate better adherence | 6 months, 12 months, 24 months | |
| Secondary | Diabetic knowledge | 23 items Michigan Diabetes Research and Training Center's revised Diabetes Knowledge Test - Max Score of 23, Min score of 0, the higher the score the better the knowledge | 6 months, 12 months, 24 months | |
| Secondary | Diabetic self-care | Self-Care Inventory-Revised Version (SCI-R) scale- Max sore of 15, min score of 15 - the higher the score the better the self-care | 6 months, 12 months, 24 months | |
| Secondary | Diabetes distress survey | Problem Areas in Diabetes Scale (PAID), Max score of 80, min score of 0, the lower the core the better (lesser distress) | 6 months, 12 months, 24 months | |
| Secondary | Healthcare utilization | Healthcare cost | 6 months, 12 months, 24 months | |
| Secondary | Incidence of vascular complications | Incidence of both micro- and macro- vascular complication | 6 months, 12 months, 24 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |